Therapeutic Breakthroughs in Atherosclerosis: From Bench to Bedside A Symposium Presented by IAS and SHA
- 5 – 6 December, 2025
- Crowne Plaza RDC, Riyadh
- 00Days
- 00Hours
- 00Minutes
- 00Seconds
Welcome Message
Dear Colleagues and Distinguished Guests,
On behalf of the Scientific Committee, it is our great honour and pleasure to welcome you to the International Atherosclerosis Society (IAS) & Saudi Heart Association (SHA) Symposium on “Therapeutic Breakthroughs in Atherosclerosis: From Bench to Bedside” held in the vibrant and cosmopolitan city of Riyadh, Kingdom of Saudi Arabia, on December 5-6, 2025.
This symposium brings together leading international and regional experts to address some of the most pressing problems and innovative solutions in the fight against atherosclerosis.
Our scientific programme covers a wide range of subjects, including precision medicine, artificial intelligence (AI) and omics, cardiometabolic kidney disease, diabetes, obesity, and MAFLD, lipoprotein (a), genetic dyslipidaemias, residual risk and remnant cholesterol, and controversies in inflammation.
We are also pleased to host a special lecture on “Lethal Lipid Inertia and Social Media”, which will illustrate how rampant disinformation threatens the major scientific advancements of the last few decades and how communication in medicine needs to improve to counter this threat to the safety and well-being of our patients.
The symposium will foster the exchange of cutting-edge knowledge and practical insights, facilitating collaboration among clinicians, scientists, and healthcare professionals dedicated to advancing the prevention and treatment of atherosclerotic diseases. We hope the sessions stimulate thought-provoking discussions and inspire new research and clinical strategies to benefit our patients and communities.
Beyond the academic programme, we encourage you to enjoy your stay in Riyadh, a city renowned for its rich heritage, dynamic culture, and warm hospitality. May your experience here be both intellectually rewarding and personally enjoyable.
We look forward to your active participation and wish you a memorable and fruitful symposium.
Dr. Fahad Alnouri
- Elected Member at Large, International Atherosclerosis Society
- Chair of the Scientific Committee
Professor Dirk Blom
- President, International Atherosclerosis Society (IAS)
Event Objectives
Precision Medicine & AI in Risk Prediction
Discuss how precision medicine, artificial intelligence, and multi-omics approaches are reshaping risk assessment, early diagnosis, and individualized treatment in cardiometabolic and kidney diseases.
Bridging Heart, Metabolic & Kidney Disorders
Present recent clinical and translational findings on the intersection of cardiovascular, metabolic, and renal diseases, focusing on shared mechanisms and integrated management strategies
Metabolic Dysfunction & Complications
Examine how metabolic dysfunction—including type 2 diabetes, obesity, and MAFLD—contributes to cardiovascular and renal complications, and identify early intervention opportunities.
Emerging Therapeutics for Metabolic Disease
Evaluate novel and emerging therapeutic options (pharmacologic and non-pharmacologic) for metabolic diseases and their implementation in clinical care.
Lipoprotein(a) & Inherited Lipid Disorders
Update clinicians and researchers on the role of lipoprotein(a) and other inherited lipid disorders in atherosclerotic cardiovascular disease, with emphasis on diagnosis, screening, and risk stratification.
Familial Hypercholester-olemia: Genetics & Care
Enhance understanding of the pathophysiology, genetic basis, and clinical presentation of FH and evaluate current and emerging therapeutic strategies—including novel lipid-lowering agents and gene therapies—to improve outcomes in the ultra-high-risk population of HoFH patients.
Inflammation & Residual Cardiovascular Risk
Explore current evidence and controversies regarding inflammation as a driver of atherosclerosis, and the evolving role of anti-inflammatory therapies in residual cardiovascular risk.
Remnant Cholesterol & Triglyceride Pathways
Define residual cardiovascular risk in treated patients, with a focus on remnant cholesterol and triglyceride-rich lipoproteins, and review emerging treatments addressing these pathways.
Scientific committee
Dr. Fahad Alnouri
(Saudi Arabia)
Committee Chair
Elected Member at Large, International Atherosclerosis Society
Chair of the Scientific Committee
Prof. Frederick J. Raal
(South Africa)
Director, Carbohydrate and Lipid Metabolism Research Unit Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Prof. Dirk Blom
(South Africa)
Associate Professor and Director, Division of Lipidology, University of Cape Town
Prof. Samia Mora
(USA)
Professor of Medicine, Harvard Medical School
Director, Center for Lipid Metabolomics
Dr. Ahmad AlSarraf
(Kuwait)
Ministry of Health, Kuwait
Dr. Nasreen AL-Sayed
(Bahrain)
Consultant Endocrinologist & Lipidologist
Chief Medical Officer
Dar Alsaha Medical Center
Dr. Khalid Al Waili
(Oman)
Clinical Biochemist and Lipidologist, Sultan Qaboos University Hospital
Dr. Carine Ayoub
(Lebanon)
Associate Professor and Researcher,
Saint Joseph University of Beirut, Lebanon
Dr. Hani Sabbour
(UAE)
Consultant Cardiologist, Cleveland Clinic Abu Dhabi
Dr. Michelle Winokur
(USA)
Executive Director, International Atherosclerosis Society (IAS)
Agenda
Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.